Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults

Journal of the International Association of Providers of AIDS Care (JIAPAC)

Volumn 10, Issue 4, 2011, Pages 232-238

  Clay, Patrick G ^a   Mcrae, Marypeace ^a   Laurent, Jean Pierre ^b  

^a KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

^b Koronis Pharmaceuticals   (United States)

Author keywords

antiretroviral; HIV AIDS; KP 1212; KP 1461; pharmacokinetics; phase I

Indexed keywords

CYTIDINE DERIVATIVE; KP 1461; PLACEBO; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS LOAD; DOSE RESPONSE; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VIRAL LOAD;

EID: 80052836937     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/1545109711406442     Document Type: Review

References (16)

1. Chen R Yokoyama M Sato H Reilly C Mansky LM. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies. J Virol. 2005;79(18):12045–12057.
2. Ferrer-Orta C Arias A Perez-Luque R Escarmis C Domingo E Verdaguer N. Sequential structures provide insights into the fidelity of RNA replication. Proc Natl Acad Sci U S A. 2007;104(22):9463–9468.
3. Overbaugh J Bangham CR. Selection forces and constraints on retroviral sequence variation. Science. 2001;292(5519):1106–1109.
4. Anderson JP Daifuku R Loeb LA. Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol. 2004;58:183–205.
5. Anderson PL Kakuda TN Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis. 2004;38(5):743–753.
6. Daifuku R. Stealth nucleosides: mode of action and potential use in the treatment of viral diseases. BioDrugs. 2003;17(3):169–177.
7. Eigen M. Error catastrophe and antiviral strategy. Proc Natl Acad Sci U S A. 2002;99(21):13374–13376.
8. Sivapalasingam S Essajee S Nyambi PN. Human immunodeficiency virus (HIV) reverse transcriptase activity correlates with HIV RNA load: implications for resource-limited settings. J Clin Microbiol. 2005;43(8):3793–3796.
9. Harris KS Brabant W Styrchak S Gall A Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005;67(1):1–9.
10. Harris KS Sergueev D Reno J. The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy. Retrovirology. 2006;3 (suppl 1):S13.
11. Loeb LA Essigmann JM Kazazi F Zhang J Rose KD Mullins J. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A. 1999;96(4):1492–1497.
12. Loeb LA Mullins JI. Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res Hum Retroviruses. 2000;16(1):1–3.
13. Murakami E Basavapathruni A Bradley WD Anderson KS. Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases. Antiviral Res. 2005;67(1):10–17.
14. McRae M Rezk NL Bridges AS. Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. Pharmacotherapy. 2010;30(1):17–24.
15. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda, MD: US Department of Health and Human Services; 2004. http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf. Accessed April 19, 2011.
16. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1 -166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 19, 2011.